<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU

    111, Inc.

    111,Inc., co-founded by Gang Yu and Junling Liu in 2010, is a leading digital and ...

    111,Inc., co-founded by Gang Yu and Junling Liu...

    Filing Type:    PU
    Dyadic International, Inc.

    Dyadic International, Inc.

    Dyadic International, Inc. is a global biotechnology company based in Jupiter, Flo...

    Dyadic International, Inc. is a global biotechn...

    Filing Type:    PU
    EDAP TMS S.A.

    EDAP TMS S.A.

    Global leader in therapeutic ultrasound and present in the market for more than 35...

    Global leader in therapeutic ultrasound and pre...

    Filing Type:    PU
    Affimed Therapeutics

    Affimed Therapeutics

    At Affimed, we are committed to improving outcomes for patients with cancer. Our s...

    At Affimed, we are committed to improving outco...

    Filing Type:    PU
    Dante Labs International LLC

    Dante Labs International LLC

    Dante Labs is a genetic testing and data analysis company specialized in Whole Gen...

    Dante Labs is a genetic testing and data analys...

    Amount Raised:    $506,567.00
    Fundraising Status:    VT
    Filing Type:    CF
    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...

    Harpoon Therapeutics is a clinical-stage immuno...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Precision BioSciences, Inc.

    Precision BioSciences, Inc.

    Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...

    Precision BioSciences is dedicated to improving...

    Filing Type:    PU
    Genomic Health, Inc.

    Genomic Health, Inc.

    Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...

    Genomic Health, Inc. (NASDAQ: GHDX) is the worl...

    Filing Type:    PU
    Curis, Inc.

    Curis, Inc.

    Curis is a biotechnology company focused on the development and commercialization ...

    Curis is a biotechnology company focused on the...

    Filing Type:    PU
    Verastem, Inc.

    Verastem, Inc.

    Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committ...

    Verastem Oncology (Nasdaq: VSTM) is a commercia...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.